In the European pharmaceutical industry, there were 103 M&A deals announced in Q2 2023, worth a total value of $9.6bn, according to GlobalData’s Deals Database. The $6.1bn acquisition of dechra pharmaceuticals by freya bidco was the industry’s largest disclosed deal. A thorough analysis of the disruptive themes, the M&A activity and most notable deals are included in GlobalData’s Pharma Industry Mergers and Acquisitions Deals by Top Themes report. Buy the report here.

In value terms, M&A activity in Europe increased by 104% in Q2 2023 compared with the previous quarter’s total of $4.7bn and rose by 439% as compared to Q2 2022. Related deal volume increased by 37% in Q2 2023 versus the previous quarter and was 102% higher than in Q2 2022.

The top-ranked financial advisors supporting these M&A deals in Europe in Q2 2023 were KPMG International Coop; Bank of America; Clearwater International with 4, 3, 3 deals respectively.

The top-ranked legal advisors supporting these M&A deals in Europe Q2 2023 were CMS Legal Services EEIG; Baker & McKenzie; White & Case with 10, 5, 5 deals respectively.

For further understanding of GlobalData's Pharma Industry Mergers and Acquisitions Deals by Top Themes, buy the report here.

This content was updated on 18 July 2023

Premium Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.